Enlivex Receives FDA RMAT Designation For Osteoarthritis Immunotherapy Allocetra™

A clinical-stage immunotherapy designed to tackle one of the world’s most common age-related conditions has received a significant regulatory boost in the United States.

Israeli biotech and healthtech company Enlivex has announced that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra™, its investigational immunotherapy for age-related symptomatic knee osteoarthritis in adults aged 64 and older.

While the designation isn’t an approval just yet, it’s an important milestone for the company and could help accelerate the development pathway for a treatment area that has historically seen relatively little innovation.

What Is RMAT Designation?

RMAT designation is reserved for regenerative medicine therapies that show early clinical evidence of potential benefit in serious conditions with unmet medical needs.

Introduced under the 21st Century Cures Act, the programme is designed to help promising therapies reach patients more quickly through closer collaboration with the FDA.

Companies awarded RMAT status can receive more frequent guidance from regulators and may become eligible for accelerated approval pathways, priority review and other mechanisms designed to speed up development and assessment.

Dr. Oren Hershkovitz, Chief Executive Officer of Enlivex, explains that the designation is “a mechanism for a more efficient path through development and review, not a shortcut around the evidence that is still required.”

For healthtech and biotech companies, securing RMAT designation is often viewed as an important validation point, because it signals that regulators believe the underlying clinical data warrants closer attention. It’s a big, important step towards approval.

Why Osteoarthritis Research Is So Important

Knee osteoarthritis is one of the most common causes of pain and disability among older adults.

According to Enlivex, more than 32 million Americans currently live with the condition, with that figure projected to rise to approximately 78 million by 2040 as populations continue to age.

Current treatments largely focus on managing symptoms through pain relief, physiotherapy, injections and, in severe cases, total knee replacement surgery. Few therapies are designed to modify the underlying disease process itself.

That’s where Allocetra aims to differentiate itself in the market. Dr. Hershkovitz explains that “current options for knee osteoarthritis, including anti-inflammatory drugs, intra-articular injections and physical therapy, manage symptoms until the joint deteriorates to the point of total knee replacement. Allocetra™ is designed to address the inflammatory process associated with the disease by reprogramming macrophages toward a homeostatic state, a mechanism distinct from symptom management.”

Rather than simply targeting pain, the therapy is designed to work with the body’s immune system to address inflammation associated with ageing, which researchers increasingly believe plays a role in the progression of osteoarthritis.

The Data Behind The Designation

The FDA’s decision was based on results from Enlivex’s completed Phase I/IIa clinical trial.

According to the company, patients with primary age-related knee osteoarthritis who received Allocetra experienced statistically significant and clinically meaningful improvements in both knee pain and physical function compared with placebo. The reported benefits remained durable for at least six months following treatment.

Those results prompted Enlivex to move forward with a larger Phase IIb study.

The ongoing randomised, controlled trial is being conducted across sites in the United States and Europe and is expected to enrol 182 patients aged 64 and older. The company has already announced dosing of the first patient at a US clinical site, with top-line results expected by the end of the second quarter of 2027.

What Happens Next?

As part of the RMAT designation process, the FDA has requested a Type B meeting with Enlivex to discuss the development programme and future clinical plans.

The meeting is expected to focus on key elements of the ongoing Phase IIb study as well as potential pathways towards future pivotal trials.

Dr. Hershkovitz described the designation as an important milestone for the healthtech company.

“Receiving RMAT designation for Allocetra™ is an important milestone that underscores the strength of our clinical data in age-related knee osteoarthritis and supports our decision to focus development on the patient population that demonstrated the most pronounced benefit,” he said.

A Growing Opportunity For Healthtech

The announcement highlights a broader trend across healthcare innovation, where companies are increasingly exploring ways to address age-related diseases before they progress to more severe stages.

As populations age across the US, UK and Europe, conditions like osteoarthritis are putting more and more pressure on healthcare systems. Unsurprisingly, that’s created significant interest in therapies that could potentially slow disease progression rather than simply manage symptoms.

Whilst Allocetra remains an investigational therapy and further clinical studies will be required before any potential approval, the FDA’s decision signals that regulators see enough promise in the early data to support an accelerated development pathway.

For Enlivex, it represents an important step forward. For the wider healthtech sector, this is another example of how immunotherapy and regenerative medicine are increasingly being applied beyond areas such as cancer and rare diseases to tackle some of the most widespread conditions associated with ageing.